Stereotaxis to Showcase Innovations at Investor Conferences
ST. LOUIS – A leader in surgical robotics for minimally invasive endovascular interventions, Stereotaxis has announced that David Fischel, the Chairman and CEO, will represent the company at two important investor conferences.
Details of the Conferences
Mr. Fischel is set to provide an overview of Stereotaxis' business at the H.C. Wainwright 26th Annual Global Investment Conference. His presentation will take place on Wednesday, September 11, at 12:30 pm EST, and he will also be available for one-on-one meetings on the same day.
Insights on Conference Participation
Furthermore, Mr. Fischel will participate in one-on-one meetings on Thursday, September 12, during the Lake Street 8th Annual Best Ideas Growth Conference. These conferences offer a valuable chance for engagement with investors, allowing discussions on the company’s strategic direction and technological advancements.
Company's Vision and Mission
Stereotaxis aims to discover, develop, and deliver robotic systems, instruments, and information solutions specifically designed for the interventional laboratory. Their innovative technologies focus on enhancing patient care by improving the safety and precision of procedures, while also increasing access to minimally invasive therapies.
Global Impact
With a strong track record, Stereotaxis has treated over 100,000 patients globally, highlighting their commitment to providing cutting-edge healthcare solutions. The technologies they offer enable physicians to perform procedures with greater connectivity and intelligence, significantly improving patient outcomes.
Future Outlook
By participating in these investor conferences, Stereotaxis demonstrates its commitment to engaging with stakeholders and investors. There is considerable anticipation regarding the company’s future projects and innovations as it seeks to leverage its surgical robotics technologies.
Meeting Expectations
David Fischel's participation in these conferences will provide investors with a platform to learn more about Stereotaxis' ongoing and future initiatives. The one-on-one meetings will facilitate deeper discussions about the company's growth strategies while maintaining its leadership in the surgical robotics sector.
Stereotaxis Contacts
For further information, David L. Fischel, Chairman and Chief Executive Officer, along with Kimberly Peery, Chief Financial Officer, are available for inquiries. You can reach them at 314-678-6100 or via email at Investors@Stereotaxis.com.
Frequently Asked Questions
What is Stereotaxis known for?
Stereotaxis is recognized as a leader in surgical robotics, particularly for minimally invasive endovascular procedures.
Who will be presenting at the investor conferences?
David Fischel, the Chairman and CEO of Stereotaxis, will be the presenter.
What is the mission of Stereotaxis?
The mission of Stereotaxis is to improve interventional techniques through robotic systems and solutions that enhance patient care.
How many patients have been treated with Stereotaxis technology?
Over 100,000 patients have successfully been treated using Stereotaxis technology worldwide.
How can investors get in touch with Stereotaxis?
Interested investors can reach out to Stereotaxis by calling 314-678-6100 or emailing Investors@Stereotaxis.com.